Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: The ALTE-DOSE study
Hemodialysis catheter (HDC) dysfunction due to thrombosis is common, and dysfunction incidence can reach up to 50% within 1 year of use. Although administration of intraluminal alteplase (tissue plasminogen activator [tPA]) is the standard of practice to pharmacologically restore HDC function, there...
Gespeichert in:
| Veröffentlicht in: | Hemodialysis international 2013-07, Vol.17 (3), p.434-440 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 440 |
|---|---|
| container_issue | 3 |
| container_start_page | 434 |
| container_title | Hemodialysis international |
| container_volume | 17 |
| creator | Yaseen, Obead El-Masri, Maher M. El Nekidy, Wasim S. Soong, Derrick Ibrahim, Mohammed Speirs, John W. Kadri, Albert |
| description | Hemodialysis catheter (HDC) dysfunction due to thrombosis is common, and dysfunction incidence can reach up to 50% within 1 year of use. Although administration of intraluminal alteplase (tissue plasminogen activator [tPA]) is the standard of practice to pharmacologically restore HDC function, there are no evidence‐based guidelines concerning the optimal tPA dose. The purpose of this study was to compare the efficacy of 1.0‐mg vs. 2.0‐mg tPA dwell protocols in restoring the HDC function in thrombotic dysfunctional catheters. A retrospective, single‐center study was conducted on two independent cohorts of patients; the first (n = 129) received 2.0 mg tPA/catheter lumen, while the second (n = 108) received 1.0 mg tPA/catheter lumen. Kaplan–Meier and Cox regression analyses were performed to compare the catheter survival time between patients who received 1.0 mg tPA and those who received 2.0 mg tPA. Catheter removal occurred in 25 (19.4%) of those catheters treated with 1.0 mg tPA compared with 11 (10.2%) of catheters treated with 2.0 mg tPA (P = 0.05). The hazard ratio (HR) for catheter removal was 2.75 (95% confidence interval [95%CI] = 1.25–6.04) for the 1.0‐mg tPA cohort compared with the 2.0‐mg tPA cohort. Correction added on 3 December 2012, after first online publication: The tPA cohort values were changed. Female gender (HR = 2.51; 95%CI = 1.20–5.27) and age (HR = 0.96; 95%CI = 0.94–0.98) were also associated with catheter survival. Our findings suggest that treatment of dysfunctional HDC with 2.0‐mg tPA dwells is superior to 1.0‐mg tPA dwells. |
| doi_str_mv | 10.1111/hdi.12004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1372078109</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1372078109</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3984-1b11c95b6086711a39fd2744e3c9fede19e7640a7e1d00b896173bd4fb02415e3</originalsourceid><addsrcrecordid>eNp1kU1v1DAQhiMEoqX0wB9APraHbD2xEyfcynb7gVb0a1G5WU4y2RiSeLGdlv0l_F1c0vbGXDwjPfNo5DeKPgCdQaijttYzSCjlr6JdSHkSc5Hmr0PPiyQWKUt3onfO_aA0AUqzt9FOwkBkkMFu9Gdu-o2y2pmBmIaozuOmUw7JgdfOjUgep14PZo0DUZXX98obe0havW7j2gTw3s1IZx6mYWONN5XpiB6IRRdQPaxJi72pteq2TjtSKd-iR0uacQg-M3wiqxbJ8XK1iE8ubxfE-bHevo_eNKpzuP_07kXfTher-Xm8vDy7mB8v44oVOY-hBKiKtMxongkAxYqmTgTnyKqiwRqhQJFxqgRCTWmZFxkIVta8KWnCIUW2Fx1M3nD5rzFcLHvtKuw6NaAZnQQmEipyoEVADye0ssY5i43cWN0ru5VA5WMOMuQg_-UQ2I9P2rHssX4hnz8-AEcT8KA73P7fJM9PLp6V8bShncffLxvK_pSZYCKVd1_P5JfTm7ur28_X8jv7C5DNoqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1372078109</pqid></control><display><type>article</type><title>Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: The ALTE-DOSE study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yaseen, Obead ; El-Masri, Maher M. ; El Nekidy, Wasim S. ; Soong, Derrick ; Ibrahim, Mohammed ; Speirs, John W. ; Kadri, Albert</creator><creatorcontrib>Yaseen, Obead ; El-Masri, Maher M. ; El Nekidy, Wasim S. ; Soong, Derrick ; Ibrahim, Mohammed ; Speirs, John W. ; Kadri, Albert</creatorcontrib><description>Hemodialysis catheter (HDC) dysfunction due to thrombosis is common, and dysfunction incidence can reach up to 50% within 1 year of use. Although administration of intraluminal alteplase (tissue plasminogen activator [tPA]) is the standard of practice to pharmacologically restore HDC function, there are no evidence‐based guidelines concerning the optimal tPA dose. The purpose of this study was to compare the efficacy of 1.0‐mg vs. 2.0‐mg tPA dwell protocols in restoring the HDC function in thrombotic dysfunctional catheters. A retrospective, single‐center study was conducted on two independent cohorts of patients; the first (n = 129) received 2.0 mg tPA/catheter lumen, while the second (n = 108) received 1.0 mg tPA/catheter lumen. Kaplan–Meier and Cox regression analyses were performed to compare the catheter survival time between patients who received 1.0 mg tPA and those who received 2.0 mg tPA. Catheter removal occurred in 25 (19.4%) of those catheters treated with 1.0 mg tPA compared with 11 (10.2%) of catheters treated with 2.0 mg tPA (P = 0.05). The hazard ratio (HR) for catheter removal was 2.75 (95% confidence interval [95%CI] = 1.25–6.04) for the 1.0‐mg tPA cohort compared with the 2.0‐mg tPA cohort. Correction added on 3 December 2012, after first online publication: The tPA cohort values were changed. Female gender (HR = 2.51; 95%CI = 1.20–5.27) and age (HR = 0.96; 95%CI = 0.94–0.98) were also associated with catheter survival. Our findings suggest that treatment of dysfunctional HDC with 2.0‐mg tPA dwells is superior to 1.0‐mg tPA dwells.</description><identifier>ISSN: 1492-7535</identifier><identifier>EISSN: 1542-4758</identifier><identifier>DOI: 10.1111/hdi.12004</identifier><identifier>PMID: 23176161</identifier><language>eng</language><publisher>Canada: Blackwell Publishing Ltd</publisher><subject>Aged ; alteplase ; catheter dysfunction ; Catheters, Indwelling ; Cohort Studies ; Dose-Response Relationship, Drug ; dosing ; Female ; Hemodialysis catheter ; Humans ; Kidney Failure, Chronic - drug therapy ; Kidney Failure, Chronic - therapy ; Male ; Middle Aged ; Prognosis ; Renal Dialysis - instrumentation ; Renal Dialysis - methods ; Retrospective Studies ; Survival Analysis ; Tissue Plasminogen Activator - administration & dosage ; Treatment Outcome</subject><ispartof>Hemodialysis international, 2013-07, Vol.17 (3), p.434-440</ispartof><rights>2012 The Authors. Hemodialysis International © 2012 International Society for Hemodialysis</rights><rights>2012 The Authors. Hemodialysis International © 2012 International Society for Hemodialysis.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3984-1b11c95b6086711a39fd2744e3c9fede19e7640a7e1d00b896173bd4fb02415e3</citedby><cites>FETCH-LOGICAL-c3984-1b11c95b6086711a39fd2744e3c9fede19e7640a7e1d00b896173bd4fb02415e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhdi.12004$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhdi.12004$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23176161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yaseen, Obead</creatorcontrib><creatorcontrib>El-Masri, Maher M.</creatorcontrib><creatorcontrib>El Nekidy, Wasim S.</creatorcontrib><creatorcontrib>Soong, Derrick</creatorcontrib><creatorcontrib>Ibrahim, Mohammed</creatorcontrib><creatorcontrib>Speirs, John W.</creatorcontrib><creatorcontrib>Kadri, Albert</creatorcontrib><title>Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: The ALTE-DOSE study</title><title>Hemodialysis international</title><addtitle>Hemodial Int</addtitle><description>Hemodialysis catheter (HDC) dysfunction due to thrombosis is common, and dysfunction incidence can reach up to 50% within 1 year of use. Although administration of intraluminal alteplase (tissue plasminogen activator [tPA]) is the standard of practice to pharmacologically restore HDC function, there are no evidence‐based guidelines concerning the optimal tPA dose. The purpose of this study was to compare the efficacy of 1.0‐mg vs. 2.0‐mg tPA dwell protocols in restoring the HDC function in thrombotic dysfunctional catheters. A retrospective, single‐center study was conducted on two independent cohorts of patients; the first (n = 129) received 2.0 mg tPA/catheter lumen, while the second (n = 108) received 1.0 mg tPA/catheter lumen. Kaplan–Meier and Cox regression analyses were performed to compare the catheter survival time between patients who received 1.0 mg tPA and those who received 2.0 mg tPA. Catheter removal occurred in 25 (19.4%) of those catheters treated with 1.0 mg tPA compared with 11 (10.2%) of catheters treated with 2.0 mg tPA (P = 0.05). The hazard ratio (HR) for catheter removal was 2.75 (95% confidence interval [95%CI] = 1.25–6.04) for the 1.0‐mg tPA cohort compared with the 2.0‐mg tPA cohort. Correction added on 3 December 2012, after first online publication: The tPA cohort values were changed. Female gender (HR = 2.51; 95%CI = 1.20–5.27) and age (HR = 0.96; 95%CI = 0.94–0.98) were also associated with catheter survival. Our findings suggest that treatment of dysfunctional HDC with 2.0‐mg tPA dwells is superior to 1.0‐mg tPA dwells.</description><subject>Aged</subject><subject>alteplase</subject><subject>catheter dysfunction</subject><subject>Catheters, Indwelling</subject><subject>Cohort Studies</subject><subject>Dose-Response Relationship, Drug</subject><subject>dosing</subject><subject>Female</subject><subject>Hemodialysis catheter</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Renal Dialysis - instrumentation</subject><subject>Renal Dialysis - methods</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tissue Plasminogen Activator - administration & dosage</subject><subject>Treatment Outcome</subject><issn>1492-7535</issn><issn>1542-4758</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1v1DAQhiMEoqX0wB9APraHbD2xEyfcynb7gVb0a1G5WU4y2RiSeLGdlv0l_F1c0vbGXDwjPfNo5DeKPgCdQaijttYzSCjlr6JdSHkSc5Hmr0PPiyQWKUt3onfO_aA0AUqzt9FOwkBkkMFu9Gdu-o2y2pmBmIaozuOmUw7JgdfOjUgep14PZo0DUZXX98obe0havW7j2gTw3s1IZx6mYWONN5XpiB6IRRdQPaxJi72pteq2TjtSKd-iR0uacQg-M3wiqxbJ8XK1iE8ubxfE-bHevo_eNKpzuP_07kXfTher-Xm8vDy7mB8v44oVOY-hBKiKtMxongkAxYqmTgTnyKqiwRqhQJFxqgRCTWmZFxkIVta8KWnCIUW2Fx1M3nD5rzFcLHvtKuw6NaAZnQQmEipyoEVADye0ssY5i43cWN0ru5VA5WMOMuQg_-UQ2I9P2rHssX4hnz8-AEcT8KA73P7fJM9PLp6V8bShncffLxvK_pSZYCKVd1_P5JfTm7ur28_X8jv7C5DNoqA</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Yaseen, Obead</creator><creator>El-Masri, Maher M.</creator><creator>El Nekidy, Wasim S.</creator><creator>Soong, Derrick</creator><creator>Ibrahim, Mohammed</creator><creator>Speirs, John W.</creator><creator>Kadri, Albert</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201307</creationdate><title>Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: The ALTE-DOSE study</title><author>Yaseen, Obead ; El-Masri, Maher M. ; El Nekidy, Wasim S. ; Soong, Derrick ; Ibrahim, Mohammed ; Speirs, John W. ; Kadri, Albert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3984-1b11c95b6086711a39fd2744e3c9fede19e7640a7e1d00b896173bd4fb02415e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>alteplase</topic><topic>catheter dysfunction</topic><topic>Catheters, Indwelling</topic><topic>Cohort Studies</topic><topic>Dose-Response Relationship, Drug</topic><topic>dosing</topic><topic>Female</topic><topic>Hemodialysis catheter</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Renal Dialysis - instrumentation</topic><topic>Renal Dialysis - methods</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tissue Plasminogen Activator - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>Yaseen, Obead</creatorcontrib><creatorcontrib>El-Masri, Maher M.</creatorcontrib><creatorcontrib>El Nekidy, Wasim S.</creatorcontrib><creatorcontrib>Soong, Derrick</creatorcontrib><creatorcontrib>Ibrahim, Mohammed</creatorcontrib><creatorcontrib>Speirs, John W.</creatorcontrib><creatorcontrib>Kadri, Albert</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hemodialysis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yaseen, Obead</au><au>El-Masri, Maher M.</au><au>El Nekidy, Wasim S.</au><au>Soong, Derrick</au><au>Ibrahim, Mohammed</au><au>Speirs, John W.</au><au>Kadri, Albert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: The ALTE-DOSE study</atitle><jtitle>Hemodialysis international</jtitle><addtitle>Hemodial Int</addtitle><date>2013-07</date><risdate>2013</risdate><volume>17</volume><issue>3</issue><spage>434</spage><epage>440</epage><pages>434-440</pages><issn>1492-7535</issn><eissn>1542-4758</eissn><abstract>Hemodialysis catheter (HDC) dysfunction due to thrombosis is common, and dysfunction incidence can reach up to 50% within 1 year of use. Although administration of intraluminal alteplase (tissue plasminogen activator [tPA]) is the standard of practice to pharmacologically restore HDC function, there are no evidence‐based guidelines concerning the optimal tPA dose. The purpose of this study was to compare the efficacy of 1.0‐mg vs. 2.0‐mg tPA dwell protocols in restoring the HDC function in thrombotic dysfunctional catheters. A retrospective, single‐center study was conducted on two independent cohorts of patients; the first (n = 129) received 2.0 mg tPA/catheter lumen, while the second (n = 108) received 1.0 mg tPA/catheter lumen. Kaplan–Meier and Cox regression analyses were performed to compare the catheter survival time between patients who received 1.0 mg tPA and those who received 2.0 mg tPA. Catheter removal occurred in 25 (19.4%) of those catheters treated with 1.0 mg tPA compared with 11 (10.2%) of catheters treated with 2.0 mg tPA (P = 0.05). The hazard ratio (HR) for catheter removal was 2.75 (95% confidence interval [95%CI] = 1.25–6.04) for the 1.0‐mg tPA cohort compared with the 2.0‐mg tPA cohort. Correction added on 3 December 2012, after first online publication: The tPA cohort values were changed. Female gender (HR = 2.51; 95%CI = 1.20–5.27) and age (HR = 0.96; 95%CI = 0.94–0.98) were also associated with catheter survival. Our findings suggest that treatment of dysfunctional HDC with 2.0‐mg tPA dwells is superior to 1.0‐mg tPA dwells.</abstract><cop>Canada</cop><pub>Blackwell Publishing Ltd</pub><pmid>23176161</pmid><doi>10.1111/hdi.12004</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1492-7535 |
| ispartof | Hemodialysis international, 2013-07, Vol.17 (3), p.434-440 |
| issn | 1492-7535 1542-4758 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1372078109 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged alteplase catheter dysfunction Catheters, Indwelling Cohort Studies Dose-Response Relationship, Drug dosing Female Hemodialysis catheter Humans Kidney Failure, Chronic - drug therapy Kidney Failure, Chronic - therapy Male Middle Aged Prognosis Renal Dialysis - instrumentation Renal Dialysis - methods Retrospective Studies Survival Analysis Tissue Plasminogen Activator - administration & dosage Treatment Outcome |
| title | Comparison of alteplase (tissue plasminogen activator) high-dose vs. low-dose protocol in restoring hemodialysis catheter function: The ALTE-DOSE study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T07%3A05%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20alteplase%20(tissue%20plasminogen%20activator)%20high-dose%20vs.%20low-dose%20protocol%20in%20restoring%20hemodialysis%20catheter%20function:%20The%20ALTE-DOSE%20study&rft.jtitle=Hemodialysis%20international&rft.au=Yaseen,%20Obead&rft.date=2013-07&rft.volume=17&rft.issue=3&rft.spage=434&rft.epage=440&rft.pages=434-440&rft.issn=1492-7535&rft.eissn=1542-4758&rft_id=info:doi/10.1111/hdi.12004&rft_dat=%3Cproquest_cross%3E1372078109%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1372078109&rft_id=info:pmid/23176161&rfr_iscdi=true |